Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Methoxyphenylacetonitrile SCHEMBL103029 | 0.89 | PKM (0.61) | MAOBNPC1POLBRAB9ASMN1; SMN2 | |
| 3-Methoxyphenylacetonitrile SCHEMBL27728444 | 0.87 | PKM (0.59) | MAOBNPC1POLBRAB9ASMN1; SMN2 | |
| 3-Methoxyphenylacetonitrile SCHEMBL29253102 | 0.87 | PKM (0.59) | MAOBNPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL1020870 | 0.86 | MAOB (0.54) | APPMAOBNPC1RAB9ASMN1; SMN2 | |
| 3-Methoxyphenylacetonitrile SCHEMBL28155308 | 0.85 | PKM (0.58) | MAOBSMN1; SMN2PKMALDH1A1HTT | |
| SCHEMBL20000873 | 0.84 | APP (0.80) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL2277105 | 0.84 | MAOB (0.68) | APPMAOBRAB9ASMN1; SMN2FFAR1 | |
| SCHEMBL2276512 | 0.84 | MAOB (0.68) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL8992958 | 0.83 | LTA4H (0.59) | MAOBSMN1; SMN2PKMALDH1A1IDO1 | |
| SCHEMBL5004118 | 0.83 | FLT3 (0.57) | MAOBPOLBPKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867358-B1 | METHOD FOR ACTIVATING OCT4 FOR INDUCTION OF PLURIPOTENT STEM CELLS | UNIV JENA (DE) | 2018-08-08 | — | — | EP | claimed |
| US-9783786-B2 | Method for activating Oct4 for induction of pluripotent stem cells | Universitatsklinikum Jena (DE) | 2017-10-10 | — | — | US | claimed |
| US-20150267173-A1 | METHOD FOR ACTIVATING OCT4 FOR INDUCTION OF PLURIPOTENT STEM CELLS | Universitatsklinikum Jena (DE) | 2015-09-24 | — | — | US | claimed |
| EP-2867358-A1 | METHOD FOR ACTIVATING OCT4 FOR INDUCTION OF PLURIPOTENT STEM CELLS | Universitätsklinikum Jena (DE) | 2015-05-06 | — | — | EP | claimed |
| WO-2014000814-A1 | METHOD FOR ACTIVATING OCT4 FOR INDUCTION OF PLURIPOTENT STEM CELLS | Universitätsklinikum Jena (DE) | 2014-01-03 | — | — | WO | claimed |
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-2867358-B1 | METHOD FOR ACTIVATING OCT4 FOR INDUCTION OF PLURIPOTENT STEM CELLS | UNIV JENA (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9783786-B2 | Method for activating Oct4 for induction of pluripotent stem cells | Universitatsklinikum Jena (DE) | 2017-10-10 | — | — | US | disclosed |
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150267173-A1 | METHOD FOR ACTIVATING OCT4 FOR INDUCTION OF PLURIPOTENT STEM CELLS | Universitatsklinikum Jena (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2008034142-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | APP 883/4885MAOB 699/4885NPC1 408/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | APP 883/4885MAOB 699/4885NPC1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.